Form 4: Emergent BioSolutions SVP Simon Lowry Reports Stock and Options Transactions

Simon Lowry, SVP, R&D, CMO of Emergent BioSolutions, reports the acquisition of restricted stock units and employee stock options.

Summary

• Simon C Lowry, SVP, R&D, CMO of Emergent BioSolutions Inc., filed a Form 4.
• On March 6, 2025, Lowry acquired 62,500 shares of common stock through restricted stock units and 62,500 employee stock options.
• The restricted stock units vest in three annual installments beginning on the day prior to the anniversary of the date of grant.
• Each restricted stock unit represents the right to receive one share of common stock of Emergent BioSolutions Inc.
• The employee stock options have an exercise price of $5.8 and vest in three equal installments beginning on the day prior to the anniversary date of the grant, expiring on March 5, 2032.
• Following the reported transactions, Lowry beneficially owns 91,982 shares of common stock and 102,999 derivative securities.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing, and the transactions themselves don't necessarily indicate positive or negative sentiment. It's a neutral event.

Positives

• The grant of restricted stock units and stock options aligns Lowry's interests with those of the company and its shareholders.
• The vesting schedules incentivize continued service with the company.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's confidence in the company's future prospects.

Stakeholder Impact

• The transactions reported in the Form 4 have a minimal direct impact on stakeholders.
• They provide transparency into executive compensation and ownership.

Key Dates